Abstract
Primary cutaneous B-cell lymphoma (PCBCL) is a heterogenous group of rare extranodal non-Hodgkin lymphomas of the skin. This group includes primary cutaneous follicle center lymphoma (PCFCL), marginal zone B-cell lymphoma (PCMZL), and diffuse large B-cell lymphoma, leg type (PCDLBCL-LT). The objective of our study was to analyze the treatment protocol and outcomes of patients treated with systemic rituximab, in isolation or in combination with other chemotherapy, for PCBCL. A retrospective search for patients with PCBCL treated with rituximab in the Mayo Clinic enterprise was performed.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
